Business Wire

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

Share

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201108005065/en/

Vifor Pharma and Angion Biomedica Corp. (Angion) announced the signing of a licensing agreement for the commercialization of ANG-3777, currently developed for treatment of delayed graft function (DGF) and cardiac surgery-associated acute kidney injury (CSA-AKI). ANG-3777 was engineered to mimic the biological activity of HGF, activating critical pathways in the body’s natural organ repair process following an acute organ injury.

Under the terms of the agreement, Vifor Pharma will receive an exclusive global license, excluding China, Taiwan, Hong Kong and Macau, for all ANG-3777 nephrology indications.Angion will receive up to USD 80 million which includes a 30 million upfront payment, a 30 million equity investment and 20 million in clinical study milestone payments. Additionally Angion is eligible to receive up to USD 260 million in market access related milestones upon approval in US and EU, further payments in the form of sales milestones, and tiered royalties on global net sales up to 40% at the high end of the royalty range.

“This agreement highlights the leadership position that Vifor Pharma has developed in the nephrology space and the fact that it has become the company of choice for organizations committed to partnering innovative nephrology focused assets“ said Stefan Schulze, Chief Executive Officer of Vifor Pharma. “Angion is an excellent partner with an outstanding expertise leading to the development of this exciting asset and other pipeline products. We look forward to working closely with Angion who will be responsible for the ongoing development program of ANG-3777 and to leveraging our commercial expertise to bring this highly promising, innovative treatment with a unique mode of action to patients suffering from DGF and CSA-AKI. These are both critical conditions, currently without any effective or approved therapies.”

“Vifor Pharma is one of the world leaders in the nephrology space and we are very excited to partner with them on the commercialization of ANG‑3777 for nephrology indications,” stated Dr. Jay Venkatesan, President and CEO of Angion. “This is a major milestone for the team at Angion who has worked for many years to develop ANG-3777 as a therapy for patients with acute kidney injuries. We look forward to phase-III data in DGF towards the end of 2021 and working with Vifor Pharma to potentially bring ANG-3777 to nephrology patients worldwide.”

Addressable patients with DGF is estimated to be about 15,000 and approximately 110,000 with CSA-AKI in the US/EU5 each year.

Angion will be responsible for conducting the ongoing nephrology-focused clinical development programs. Angion and Vifor Pharma will share responsibilities for regulatory filings in the licensed territories and Vifor Pharma will be responsible for all commercialization activities related to nephrology indications in all licensed territories.

Conference call/webcast:

Vifor Pharma will host a conference call and webcast today, 9 November 2020 at 2:00 pm (CET), to discuss the license agreement.

Conference call link to get the dial-in number (open 30 minutes prior to start of the webcast): https://conferencing.swisscom.ch/conference/x/cU-8I7D0aXQc.

Webcast link: https://stream.swisscom.ch/vifor/20201109/

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

For more information, please visit www.viforpharma.com

Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion’s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. ANG-3777 is currently in clinical trials investigating its impact on acute organ injury, including two forms of acute kidney injury and in acute lung injury. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for fibrotic diseases using a precision-medicine approach. For further information, please visit www.angion.com

About ANG-3777
ANG-3777 is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), which activates the c-Met cascade of pathways involved in tissue repair and organ repair. ANG-3777 has a substantially longer half-life than HGF and Angion believes ANG-3777 has the potential to be a first-in-class therapeutic addressing acute organ injury. The ongoing clinical trials of ANG-3777 include a placebo-controlled Phase 3 registration trial in transplant-associated acute kidney injury, also known as delayed graft function, a Phase 2 proof-of-concept trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass surgery, and a Phase 2 proof-of-concept trial in patients with acute lung injury associated with COVID-19 pneumonia. In 2018, Sinovant Sciences and Angion signed a development and licensing agreement for ANG-3777 in Greater China.

About CSA-AKI
During cardiac surgery, the use of cardiopulmonary bypass during the procedure may cause or exacerbate kidney injury as a result of reduced blood flow, non-pulsatile circulation, rupture of red blood cells creating oxidant damage and other causes. CSA-AKI is caused by many factors, including shear stress during cardiopulmonary bypass and injuries from nephrotoxic drugs and contrast agents. In addition, an important driver of CSA-AKI is ischemia-reperfusion injury, which is similar to the injury seen in DGF. There are no approved pharmacological treatments.1

About DGF
Delayed graft function is a severe form of acute kidney injury resulting from ischemia-reperfusion injury following kidney transplantation. It is distinct from transplant rejection and is most commonly seen in recipients of deceased-donor kidneys. In delayed graft function, the kidney fails to adequately filter the blood and patients require dialysis within the first week after transplantation.2 Dialysis does not treat acute kidney injury, but instead is renal replacement therapy for impaired kidneys. Patients with delayed graft function are more likely to experience transplant failure and have a higher mortality rate.3, 4, 5

References:

1

Bellomo R, et al. “Acute kidney injury.” The Lancet (2012); 380: 756-766.

2

Centers for Disease Control and Prevention. “Dialysis Safety.” October 2017.

3

Shoskes D, et al. “Delayed Graft Function in Renal Transplantation: Etiology, Managment and Long-term Significance.” The Journal of Urology (1996); 155: 1831-1840.

4

Brown, et al., “Duration of acute kidney injury impacts long-term survival after cardiac surgery. The Annals of thoracic surgery. (2010); 90(4).

5

Schnuellee, P et al., “Comparison of early renal function parameters for the prediction of 5-year graft survival after kidney transplantation.” Nephrology Dialysis Transplantation (2006); 22: 235–245.

Contact information

For Vifor Pharma:
Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com

Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com

For Angion:
Investors
Daniel Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
617-430-7576

Media
Cherilyn Cecchini, M.D.
LifeSci Communications
ccecchini@lifescicomms.com
646-876-5196

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Disruptive Tech Asean Comments That Semiconductor Industry in China Eyes on a New Beyond the Manufacturing Of 7nm Chips3.12.2020 11:00:00 CETPress release

Disruptive Tech Asean learnt from Li Ke from China Semiconductor Industry Association (CSIA) that an integrated circuit industry is vital for developing modern industries, and China is therefore imperative to localize chip industry supply chain and develop homegrown-core chips. Li Ke believes that China will have the ability to fully mass-produce its own 28nm chips in one or two years, as well as having a completely domestic industry chain and independent chip manufacturing capabilities. According to Gartner’s forecast at the end of 2019, the global semiconductor market would grow by 12.5% in 2020. Yet, with devastating impacts of the COVID-19 pandemic, the forecast was revised to a decline of 0.9%. According to Andrew Norwood, Research Vice President at Gartner, “COVID-19 has distorted supply chain and manufacturing operations across the world and will lead to a drastic drop in consumer and enterprise spending across most areas with a few exceptions.” The US-China trade war has also c

LivaNova and Gyrus Capital Enter into Agreement for the Purchase of Heart Valve Business3.12.2020 11:00:00 CETPress release

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, and Gyrus Capital (Gyrus), an investment firm dedicated to investments in the healthcare and sustainability sectors, today announced they have entered into an agreement whereby entities funded and controlled by Gyrus will acquire the LivaNova heart valve (HV) business. The LivaNova Board of Directors unanimously approved the divestiture, which it believes will enable the Company to sharpen its focus within its primary platforms, neuromodulation and cardiovascular, and to dedicate increased resources toward executing its promising pipeline opportunities. Once the transaction is complete, Gyrus intends to focus management attention and investment on the HV business to position it to become a leading player in the surgical heart valve market globally, translating into even greater opportunities for employees, customers and patients. This press release features multimedia. View the full release here: ht

Telefonica UK (O2) and IDEMIA Working to Securely Connect 23 Million Homes in the UK With Smart Meters By 20253.12.2020 10:30:00 CETPress release

O2 in partnership with IDEMIA, the global leader in Augmented Identity, has today supplied secure connectivity to over 4 million UK homes with a second generation Smart Meter. The rollout will continue into the future, supporting the UK government program to deploy Smart Meters for all UK households and small businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201203005370/en/ (Photo: Business Wire) As part of the transition to a flexible energy market that requires a low carbon economy and sustainable consumption habits, smart meters give consumers near real-time information on energy helping them to take control of their energy usage and bring an end to estimated billing. Smart meters come with in-home displays to enable consumers to have a better understanding of their energy usage. Against that backdrop, customers using the latest generation of smart meters are reporting an average saving of around 10% per month.

Measuring What Matters: A New Approach to Assessing Sovereign Climate Risk3.12.2020 09:23:00 CETPress release

Moody’s affiliate Four Twenty Seven today released a report analyzing the future exposure of the global population, the economy, and agriculture to a range of climate hazards, exploring both global trends and findings by country. Leveraging new analytics developed by Four Twenty Seven, the report assesses exposure to floods, heat stress, hurricanes and typhoons, rising sea levels, wildfires, and water stress and is based on the only known global dataset matching physical climate risk exposure to population location, GDP Purchasing Power Parity (PPP), and agricultural areas within countries. “This novel dataset provides a detailed view of the exposure of key human and economic assets around the world. Understanding exposure is critical for investors and credit institutions to price climate risk, but also to help direct finance flows towards adaptation and resilience where they’re most needed,” says Emilie Mazzacurati, Global Head of Moody’s Climate Solutions in Moody’s ESG Solutions Gro

PMI Commits to Disability Inclusion by Joining The Valuable 5003.12.2020 09:05:00 CETPress release

Philip Morris International Inc.(PMI) (NYSE: PM) today announced that CEO André Calantzopoulos has joined The Valuable 500—a global movement putting disability inclusion on the business leadership agenda. Signing on to this initiative marks another significant step in PMI’s journey of advancing inclusion and diversity in the workplace. André Calantzopoulos said: “Businesses with a global operating footprint, such as PMI, can make a meaningful impact by ensuring that everyone—including individuals with a disability—can prosper in the workplace. By signing The Valuable 500, I am proud to join forces with a host of other CEOs who are challenging their organizations and the business world to broaden the focus of their inclusion and diversity efforts, and to help create a more inclusive world for the 1.3 billion people with disabilities. This is the right thing to do as part of our broader work to create a more equitable society. And it is also the smart thing to do, allowing PMI to tap int

Siemens Smart Infrastructure Chooses AWS as Its Preferred Cloud Provider for SAP Environments3.12.2020 09:01:00 CETPress release

Today, Amazon Web Services (AWS), an Amazon.com company (NASDAQ: AMZN), announced that Siemens Smart Infrastructure, a business of the Siemens AG group focusing on energy distribution and intelligent buildings, is moving its SAP infrastructure to AWS. The business will migrate over 20 Enterprise Resource Planning (ERP) and Supply Chain Management (SCM) systems,based on SAP HANA, to AWS before the end of 2021. These systems support business-critical processes in areas such as manufacturing, operations, and sales across different business units including Building Products, Electrical Products, Digital Grid, and Distribution Systems. Moving these workloads to AWS will enable Siemens Smart Infrastructure to significantly shorten hardware refresh cycles, increase agility to test and deploy new systems, and provide the foundation for the company’s future transformation using SAP S/4HANA technology. This is the first migration of production-scale SAP systems to the cloud across the Siemens AG

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom